Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorisation Safety Study: A Cohort Event Monitoring Study to Characterise the Use of Eplontersen in Patients With Prior Liver Transplant and Pre-existing Severe Hepatic Impairment and to Assess Long-term Safety Among All New Users of Eplontersen (sTTRing)

NCT07654855 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07654855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorisation Safety Study: A Cohort Event Monitoring Study to Characterise the Use of Eplontersen in Patients With Prior Liver Transplant and Pre-existing Severe Hepatic Impairment and to Assess Long-term Safety Among All New Users of Eplontersen (sTTRing)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2026
Completion date
January 29, 2032
Enrollment
320 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloidosis, transthyretin amyloidosis with cardiomyopathy, transthyretin amyloidosis with polyneuropathy